FUS and myxoid liposarcoma: To identify drugs with antiproliferative activity, we screened 43 drugs for their in vitro antiproliferative activity against two myxoid liposarcoma patient-derived cell lines, MLS 402 and MLS 1765, which have both been confirmed to express FUS-CHOP [18].